Antonio Benedetti
Direktor/Vorstandsmitglied bei Cycle Pharmaceuticals Ltd.
Profil
Antonio Benedetti has worked as a Director at Cycle Pharmaceuticals Ltd.
since 2016.
Aktive Positionen von Antonio Benedetti
Unternehmen | Position | Beginn |
---|---|---|
Cycle Pharmaceuticals Ltd.
Cycle Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cycle Pharmaceuticals Ltd. is a British privately-owned biotechnology company that focuses on delivering drug treatments and services to the under-served rare disease patient community. The company is based in Cambridge, UK, and their mission is to utilize the latest pharmaceutical technologies to deliver superior drug treatments to better serve rare genetic disease patients. The company specializes in rare metabolic, immunological, and neurological genetic conditions. The company also provides individualized patient support services to meet patient needs swiftly. Cycle Pharmaceuticals works with a variety of partners to support their patients' needs through their named patient program. | Direktor/Vorstandsmitglied | 25.01.2016 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Cycle Pharmaceuticals Ltd.
Cycle Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cycle Pharmaceuticals Ltd. is a British privately-owned biotechnology company that focuses on delivering drug treatments and services to the under-served rare disease patient community. The company is based in Cambridge, UK, and their mission is to utilize the latest pharmaceutical technologies to deliver superior drug treatments to better serve rare genetic disease patients. The company specializes in rare metabolic, immunological, and neurological genetic conditions. The company also provides individualized patient support services to meet patient needs swiftly. Cycle Pharmaceuticals works with a variety of partners to support their patients' needs through their named patient program. | Health Technology |